Healthcare Industry News:  ezetimibe/simvastatin 

Biopharmaceuticals Cardiology

 News Release - June 12, 2006

New Study Showed VYTORIN(R) (ezetimibe/simvastatin) Superior to Lipitor in Reducing LDL ''Bad'' Cholesterol in Patients with Type II Diabetes at the Recommended Usual Starting Doses





Source: Merck/Schering-Plough Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.